Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 20/20 | 1.00 |
| ▸ | AGTR1 | P30556 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.84 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Buloxibutid SCHEMBL30718088 | 0.99 | AGTR2 (0.98) | AGTR2AGTR1CYP2C9CYP2B6 | |
| Buloxibutid SCHEMBL26934181 | 0.99 | AGTR2 (0.98) | AGTR2AGTR1CYP2C9CYP2B6 | |
| SCHEMBL557741 | 0.92 | AGTR2 (1.00) | AGTR2AGTR1CYP2C9CYP2B6 | |
| SCHEMBL1718514 | 0.92 | AGTR2 (1.00) | AGTR2AGTR1CYP2C9CYP2B6 | |
| SCHEMBL557104 | 0.91 | AGTR2 (1.00) | AGTR2AGTR1CYP2C9CYP2B6 | |
| SCHEMBL557333 | 0.91 | AGTR2 (1.00) | AGTR2AGTR1CYP2C9CYP2B6 | |
| SCHEMBL26130429 | 0.91 | AGTR2 (0.83) | AGTR2AGTR1CYP2C9CYP2B6 | |
| SCHEMBL557456 | 0.90 | AGTR2 (1.00) | AGTR2AGTR1CYP2C9CYP2B6 | |
| SCHEMBL5214238 | 0.90 | AGTR2 (0.94) | AGTR2AGTR1CYP2C9CYP2B6 | |
| SCHEMBL26127375 | 0.90 | AGTR2 (0.82) | AGTR2AGTR1CYP2C9CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260069572-A1 | TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS | VICORE PHARMA AB (SE) | 2026-03-12 | — | — | US | claimed |
| US-20260007608-A1 | NEW DELAYED RELEASE COMPOSITION FOR PERORAL ADMINISTRATION | VICORE PHARMA AB (SE) | 2026-01-08 | — | — | US | claimed |
| US-20250235408-A1 | NEW DELAYED RELEASE COMPOSITION FOR PERORAL ADMINISTRATION | VICORE PHARMA AB (SE) | 2025-07-24 | — | — | US | claimed |
| US-20250177355-A1 | TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS | VICORE PHARMA AB (SE) | 2025-06-05 | — | — | US | claimed |
| US-12213961-B2 | Treatment of idiopathic pulmonary fibrosis | VICORE PHARMA AB (SE) | 2025-02-04 | — | — | US | claimed |
| CN-119300823-A | Use of cloth Luo Tide for treating idiopathic pulmonary fibrosis | 维科尔药物公司 | 2025-01-10 | — | — | CN | claimed |
| EP-4475843-A1 | USE OF BULOXIBUTID FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS | Vicore Pharma AB (SE) | 2024-12-18 | — | — | EP | claimed |
| US-12128029-B2 | Treatment of idiopathic pulmonary fibrosis | VICORE PHARMA AB (SE) | 2024-10-29 | — | — | US | claimed |
| US-12121614-B2 | Delayed release composition for peroral administration | VICORE PHARMA AB (SE) | 2024-10-22 | — | — | US | claimed |
| US-20240269081-A1 | NEW DRY POWDER COMPOSITION FOR PERORAL ADMINISTRATION | VICORE PHARMA AB (SE) | 2024-08-15 | — | — | US | claimed |
| EP-3229839-A1 | NEW METHODS AND USES | Vicore Pharma AB (SE) | 2017-10-18 | — | — | EP | claimed |
| US-20170266164-A1 | NEW METHODS AND USES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-09-21 | — | — | US | claimed |
| WO-2016092329-A1 | NEW METHODS AND USES | VICORE PHARMA AB (SE) | 2016-06-16 | — | — | WO | claimed |
| US-8835471-B2 | Use of angiotensin II agonists | VICORE PHARMA AB | 2014-09-16 | — | — | US | claimed |
| US-20120035232-A1 | USE OF ANGIOTENSIN II AGONISTS | VICORE PHARMA AB | 2012-02-09 | — | — | US | claimed |
| CN-1529697-B | Tricyclic compounds useful as angiotensin II agonists | VICORE PHARMA AB | 2010-09-22 | — | — | CN | claimed |
| US-7652054-B2 | Tricyclic compounds useful as angiotensin II agonists | VICORE PHARMA AB (SE) | 2010-01-26 | — | — | US | claimed |
| US-20090326026-A1 | Tricyclic Compounds Useful as Angiotensin II Agonists | VICORE PHARMA AB | 2009-12-31 | — | — | US | claimed |
| EP-1395566-B1 | TRICYCLIC COMPOUNDS USEFUL AS ANGIOTENSIN II AGONISTS | VICORE PHARMA AB (SE) | 2007-09-12 | — | — | EP | claimed |
| US-20040167176-A1 | Tricyclic compounds useful as angiotensin II agonists | VICORE PHARMA AB (SE) | 2004-08-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167176-A1 | Tricyclic compounds useful as angiotensin II agonists | AGTR1, AGTR2, NPY2R | AGTR2 2/4885AGTR1 1/4885CYP2C9 1541/4885 |
| US-20090326026-A1 | Tricyclic Compounds Useful as Angiotensin II Agonists | AGTR2, AGTR1, NPY4R | AGTR2 1/4885AGTR1 2/4885CYP2C9 1155/4885 |
| US-20260069572-A1 | TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS | MMP1, CFTR, SLC9A1 | AGTR2 302/4885AGTR1 458/4885CYP2C9 2687/4885 |
| US-20120035232-A1 | USE OF ANGIOTENSIN II AGONISTS | AGTR1, AGTR2, REN | AGTR2 2/4885AGTR1 1/4885CYP2C9 2062/4885 |
| US-20260007608-A1 | NEW DELAYED RELEASE COMPOSITION FOR PERORAL ADMINISTRATION | TNNT2, TPMT, TNNC1 | AGTR2 438/4885AGTR1 398/4885CYP2C9 807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.